| Literature DB >> 35474107 |
Thomas L Pulliam1,2,3, Pavithr Goli1,4, Dominik Awad1,5, Chenchu Lin1,5, Sandi R Wilkenfeld1,5, Daniel E Frigo6,7,8,9,10.
Abstract
In 2011, CAMKK2, the gene encoding calcium/calmodulin-dependent kinase kinase 2 (CAMKK2), was demonstrated to be a direct target of the androgen receptor and a driver of prostate cancer progression. Results from multiple independent studies have confirmed these findings and demonstrated the potential role of CAMKK2 as a clinical biomarker and therapeutic target in advanced prostate cancer using a variety of preclinical models. Drug development efforts targeting CAMKK2 have begun accordingly. CAMKK2 regulation can vary across disease stages, which might have important implications in the use of CAMKK2 as a biomarker. Moreover, new non-cell-autonomous roles for CAMKK2 that could affect tumorigenesis, metastasis and possible comorbidities linked to disease and treatment have emerged and could present novel treatment opportunities for prostate cancer.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35474107 DOI： 10.1038/s41585-022-00588-z
Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432